Executive Team

Phil Pang photoPhil Pang, M.D., Ph.D.

Chief Medical Officer

Phil Pang, M.D., Ph.D., is the Chief Medical Officer at Vir. Previously, he served as the chief medical officer at Riboscience, a biotech startup developing small molecule antivirals. Prior to Riboscience, he was with Gilead Sciences, Inc. where he successfully led the 100+ matrix team responsible for the worldwide approval of the hepatitis C blockbuster treatment, Harvoni (sofosbuvir/ledipasivir), and the subsequent filing of eight subsequent supplemental NDAs/Type II variations expanding the patient population eligible for this treatment.